LinkedUp, TianTi end legal dispute with Adimab over yeast-based antibody platform

LinkedUp Bio­science and TianTi Bio­ther­a­peu­tics have re­solved their le­gal bat­tle with Adimab dat­ing back to 2020 con­cern­ing al­leged mis­use of trade se­crets.

The de­fen­dants, both based in Woburn, MA, inked an agree­ment un­der which Adimab’s law­suit “will be dis­missed with prej­u­dice,” with none of the par­ties ad­mit­ting wrong­do­ing. The case was orig­i­nal­ly filed at the Suf­folk Coun­ty Su­pe­ri­or Court in Mass­a­chu­setts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.